FRAXA Research Foundation

Rating: 5 stars   58 reviews


10 Prince Place, Suite 203 Newburyport MA 01950 USA


FRAXA was founded in 1994 by three parents of children with Fragile X. Our mission is to accelerate research aimed at finding effective treatments and a cure for Fragile X and related disorders, by directly funding grants and fellowships at top universities around the world.


We have funded $23 Million in targeted research and are on the verge of bringing a treatment for Fragile X - and perhaps also autism - to patients.

Target demographics:

find effective treatments and ultimately a cure for all children and adults who have Fragile X syndrome

Direct beneficiaries per year:

20 research teams to find new treatments for Fragile X; half of them have now gone on to receive large grants from the National Institutes of Health.

Geographic areas served:

the U.S., Canada, Europe, South America, and Australia


1) Research grants and fellowships to fund research on Fragile X Syndrome, autism, and related disorders at universities around the world. 2) The FRAXA drug validation initiative (FRAXA-DVI), where we can provide preclinical testing of potential new medications for Fragile X; we have provided this service to a dozen pharmaceutical companies and now several of them are conducting clinical trials.

2016 Top-Rated Nonprofit
Write a Review
Invite Reviews Share This Nonprofit

See How 3Hrs Can Help

More Info


Promote This Nonprofit

GreatNonprofits badges allow you to raise awareness of your favorite nonprofits on your own web sites!

Review this charity on

Reviews for FRAXA Research Foundation

Rating: 5 stars  

3 people found this review helpful

I have interacted with FRAXA since 2006, acting as a researcher working in development of new medicines for Fragile X Syndrome. What attracted me to FRAXA in the first instance, and continues to be true today, is the role FRAXA has played in putting Fragile X Syndrome on the radar of the pharmaceutical industry. I can remember the days when there were no clinical stage investigations of novel potential therapeutic approaches to Fragile X Syndrome. Now there is an industry wide pipeline of programs in development across many companies. I think it is a simple truth that without FRAXA this would not be the case. The initiatives FRAXA has in place have, and continues to be, crucial to this critical mass of effort to find new options for people with lives touched by Fragile X Syndrome.

Flag review